|
|
 |
|
Viewing report
|
|
 |
 |
T-Cell Lymphomas - Pipeline Review, Q4 2010
Global Markets Direct, Dec 2010, Pages: 61
T-Cell Lymphomas - Pipeline Review, Q4 2010
Summary
Global Markets Direct’s, “T-Cell Lymphoma Pipeline Review, Q4 2010”, provides an overview of the T-Cell Lymphoma therapeutic pipeline. This report provides information on the therapeutic development for T-Cell Lymphoma , complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for T-Cell Lymphoma . “T-Cell Lymphoma -Pipeline Review 2010, Q4 2010” is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Scope
- A snapshot of the global therapeutic scenario for T-Cell Lymphoma . - A review of the T-Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the T-Cell Lymphoma pipeline on the basis of therapeutic class, route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products.
Reasons to buy
- A snapshot of the global therapeutic scenario for T-Cell Lymphoma . - A review of the T-Cell Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the T-Cell Lymphoma pipeline on the basis of therapeutic class, route of administration and molecule type. - Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress. - Key discontinued pipeline projects. - Latest news and deals relating to the products.
|
 |
|
|